Neogen (NEOG) Asset Writedowns and Impairment (2023 - 2025)
Neogen's quarterly Asset Writedowns and Impairment came in at -$470.8 million in Q2 2025, down 23009.98% quarter-over-quarter from $2.1 million in Q1 2025.
Neogen has reported Asset Writedowns and Impairment for 3 years, with the latest figure at -$470.8 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Neogen | 1.94 Bn | 1.78 Bn | 99.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2025 | -470.80 Mn |
| May 31, 2025 | -470.80 Mn |
| Feb 28, 2025 | 2.06 Mn |
| Feb 28, 2025 | 2.06 Mn |
| Feb 29, 2024 | -716,000.00 |
| Feb 29, 2024 | -716,000.00 |
| May 31, 2023 | -2.30 Mn |
| May 31, 2023 | -2.30 Mn |